Nipocalimab for Sjogren's Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing nipocalimab, a medicine that targets harmful immune proteins, in people with primary Sjogren's syndrome. The goal is to see if it can reduce inflammation and improve symptoms in these patients.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have taken oral cyclophosphamide in the last 3 months or intravenous cyclophosphamide in the last 6 months, you may not be eligible to participate.
How is the drug Nipocalimab different from other treatments for Sjogren's Syndrome?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either nipocalimab or placebo intravenously every 2 weeks for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nipocalimab
- Placebo
- Standard of Care Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University